Tag: Campylobacter and Enterotoxigenic Escherichia coli
Immuron prepares for diarrhoea-focused clinical trial as US FDA lifts clinical hold
Immuron, an Australia-based biopharmaceutical company, is slated to move forward with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) following approval from the US Food and Drug Administration (FDA).
Featured Article
Australian Manufacturing Week 2026 enters final run-up to Brisbane debut
Australia’s manufacturing sector continues to play a critical role in the national economy, underpinned by ongoing investment in advanced technologies, automation, and high-value production.
